San Francisco Business Times – 2:51 PM PST Thursday
Cytokinetics Inc. said Thursday that a clinical trial of ispinesib, an experimental lung cancer treatment, failed.
The South San Francisco drug company (NASDAQ: CYTK) said the Phase II trial, run by GlaxoSmithKline, failed to meet the criteria to advance to the next stage of clinical testing.
The drug had been given to patients with platinum-sensitive non-small cell lung cancer.
Cytokinetics focuses on drugs that work on the cytoskeleton, a structure of protein filaments that give shape to cells.
Published March 30, 2006 by San Francisco Business Times
 |  |
(No Ratings Yet)
Loading ...
Addiction
NOTE: The contents in this blog are for informational purposes only, and should not be construed as medical advice, diagnosis, treatment or a substitute for professional care. Always seek the advice of your physician or other qualified health professional before making changes to any existing treatment or program. Some of the information presented in this blog may already be out of date.
“Battling For Health” blog seeks to bring you the latest in all of the health news, opinion, resources, and off-beat stories. If you want to know about it – we do too. There are also other reasons to enter your email address and click the Submit button below the line! :D
